14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
SBC vs RYOJ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, SBC Medical Group Holdings Incorporated (SBC) is the stronger overall head-to-head candidate over rYojbaba Co., Ltd. Common Shares (RYOJ) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SBC carries a Unified Composite Score of 38.7/100 (SELL) at $5.60 (10.2x Forward P/E, 39.9% operating margin), whereas RYOJ carries 42.9/100 (HOLD) at $2.23 (N/M Forward P/E, -8.1% operating margin).
Composite vs. Pillar Nuance: While RYOJ currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. SBC 38.7/100 SELL), SBC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (39.9% vs. -8.1% operating margin) and revenue trajectory (+35.1% vs. -34.3% YoY).
Technical & Structure Timing Caution: SBC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.8); meanwhile RYOJ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SBC vs RYOJ. Trailing 12-month operating profitability (SBC 39.9% vs RYOJ -8.1%) and valuation multiples (SBC 10.2x vs RYOJ N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Consulting Services value chain with $26.0M market capitalization and -8.1% operating margin.
OpEx & R&D Reinvestment34.7% of Rev ($3.2M)
90D Engineering Disclosures0 Published
Investor FAQ SBC vs RYOJ Key Questions & Quantitative Answers
As of Nov 19, 2026, SBC Medical Group Holdings Incorporated (SBC) is the stronger overall head-to-head candidate over rYojbaba Co., Ltd. Common Shares (RYOJ) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SBC carries a Unified Composite Score of 38.7/100 (SELL) at $5.60 (10.2x Forward P/E, 39.9% operating margin), whereas RYOJ carries 42.9/100 (HOLD) at $2.23 (N/M Forward P/E, -8.1% operating margin). Composite vs. Pillar Nuance: While RYOJ currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. SBC 38.7/100 SELL), SBC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (39.9% vs. -8.1% operating margin) and revenue trajectory (+35.1% vs. -34.3% YoY). Technical & Structure Timing Caution: SBC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.8); meanwhile RYOJ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SBC leads the Growth & Scale pillar: SBC posts +35.1% YoY revenue growth and +22.4% YoY earnings growth on $190M TTM revenue (72.2% gross margin, 39.9% operating margin), compared with RYOJ at -34.3% YoY revenue growth and +11.8% YoY earnings growth on $9.3M TTM revenue (26.6% gross margin, -8.1% operating margin). On trailing 12-month operating scale, SBC generates $190M in USD-normalized revenue versus $9.3M for RYOJ. In operating R&D and SG&A reinvestment, SBC deploys 32.3% of Rev ($61M) (0 90-day corporate R&D disclosures) versus 34.7% of Rev ($3.2M) (0 disclosures) for RYOJ.
SBC screens cheaper on headline valuation multiples. SBC trades at 10.2x Forward P/E, 12.3x Trailing P/E, 2.35x PEG, and 3.4x EV/Revenue (41.8% EBITDA margin), whereas RYOJ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.8x EV/Revenue (-0.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SBC (19.3% ROE) versus RYOJ (2.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SBC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 156% Vol realized risk). By comparison, RYOJ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.68β · 92% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.